Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Cash Flow (2020 - 2025)

Mirum Pharmaceuticals has reported Net Cash Flow over the past 6 years, most recently at $16.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $16.1 million for Q4 2025, up 1660.35% from a year ago — trailing twelve months through Dec 2025 was $72.0 million (up 215.96% YoY), and the annual figure for FY2025 was $72.0 million, up 215.96%.
  • Net Cash Flow for Q4 2025 was $16.1 million at Mirum Pharmaceuticals, down from $53.6 million in the prior quarter.
  • Over the last five years, Net Cash Flow for MIRM hit a ceiling of $147.9 million in Q2 2023 and a floor of -$69.2 million in Q2 2024.
  • Median Net Cash Flow over the past 5 years was $3.7 million (2021), compared with a mean of $7.7 million.
  • Biggest five-year swings in Net Cash Flow: crashed 265.78% in 2024 and later soared 1660.35% in 2025.
  • Mirum Pharmaceuticals' Net Cash Flow stood at $75.5 million in 2021, then crashed by 110.39% to -$7.8 million in 2022, then tumbled by 114.78% to -$16.8 million in 2023, then surged by 105.42% to $913000.0 in 2024, then soared by 1660.35% to $16.1 million in 2025.
  • The last three reported values for Net Cash Flow were $16.1 million (Q4 2025), $53.6 million (Q3 2025), and $14.1 million (Q2 2025) per Business Quant data.